Django Sussman
Pfizer (United States)(US)
Publications by Year
Research Areas
HER2/EGFR in Cancer Research, Monoclonal and Polyclonal Antibodies Research, Cell Adhesion Molecules Research, RNA and protein synthesis mechanisms, CAR-T cell therapy research
Most-Cited Works
- → SGN-CD33A: a novel CD33-targeting antibody–drug conjugate using a pyrrolobenzodiazepine dimer is active in models of drug-resistant AML(2013)383 cited
- → Computational redesign of endonuclease DNA binding and cleavage specificity(2006)340 cited
- → A Potent Anti-CD70 Antibody–Drug Conjugate Combining a Dimeric Pyrrolobenzodiazepine Drug with Site-Specific Conjugation Technology(2013)243 cited
- → Development of orally active inhibitors of protein and cellular fucosylation(2013)185 cited
- → Structural Basis of Microtubule Destabilization by Potent Auristatin Anti-Mitotics(2016)159 cited
- → SGN–LIV1A: A Novel Antibody–Drug Conjugate Targeting LIV-1 for the Treatment of Metastatic Breast Cancer(2014)129 cited
- → The structural basis for molecular recognition by the vitamin B 12 RNA aptamer.(2000)100 cited
- → Homing endonuclease I-CreI derivatives with novel DNA target specificities(2006)98 cited
- → Engineered anti-CD70 antibody-drug conjugate with increased therapeutic index(2008)96 cited
- → Characterization of SGN-CD123A, A Potent CD123-Directed Antibody–Drug Conjugate for Acute Myeloid Leukemia(2017)94 cited